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Abstract
Background: The risk of severe cardiovascular toxicity, specifically thromboembolic events (TE),
in patients with cervical cancer receiving concurrent irradiation and cisplatin chemotherapy is
reported to be less than 1% in several large prospective trials. However, the anecdotal risk appears
to be far higher.
Results and discussion: A review of several prospective trials demonstrates no treatment
related grade 4 cardiovascular toxicities and only two grade 5 toxicities in 1424 (0.1%) collective
patients. A recent publication and our own unpublished experience finds 6 of 128 (4.7%) patients
developed grade 4 to 5 cardiovascular (thrombosis/embolism) toxicity. The differenc in incidence
of severe or life threatening cardiovascular toxicity of 0.1 versus 4.7% is highly statistically significant
(p < 0.00001.)
Conclusion: This dramatic difference in incidence of cardiovascular toxicity raises the possibility
that cardiovascular toxicities were inadequately reported on the listed prospective trials. For those
patients enrolled in prospective trials, we suggest that thromboses should be diligently documented
and reported. Only after the true incidence of thromboses is established can we implement
appropriate levels of early screening and intervention that may prevent life threatening
complications.
Background
A retrospective, case control study of 147 with carcinoma
of the cervix or vagina treated with chemoradiotherapy
with or without erythropoietin showed a 23 versus 3%
incidence of TE. [1] Such recent findings of an elevated
risk of cardiovascular toxicity, specifically thromboem-
bolic events (TE), in patients receiving concurrent irradia-
tion, cisplatin chemotherapy and erythropoietin have
spurred interest in the true incidence of TE in patients
receiving concurrent irradiation and cisplatin chemother-
apy in the absence of erythropoietin.
The use of cisplatin, either alone or in combination with
other chemotherapeutic agents, has become the standard
of care for the treatment of various solid tumors. Specifi-
cally, the routine use of cisplatin in the treatment of can-
cers of the uterine cervix has been cemented with the
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publication of several recent prospective randomized tri-
als [2-8].
When reporting the results of these prospective trials, the
scoring of treatment related toxicity is site specific. For
example, TE are scored as cardiovascular toxicity and
graded from 1 to 5 on the RTOG scale (Table 1). However,
these trials often do not specify the incidence and severity
of treatment related cardiovascular (thrombotic) toxici-
ties. In fact, of the trials shown in Table 2, incidence of TE
were only specifically reported in the study by Malfetano
et al [4].
Results and discussion
A review of these prospective trials demonstrates no treat-
ment related grade 4 cardiovascular toxicities and only
two grade 5 toxicities (Table 2) in 1424 collective patients.
According to the literature then, formation of severe or life
threatening thromboses associated with cisplatin chemo-
therapy, in the absence of erythropoietin, is an exceed-
ingly rare event.
The data in table 3, however, belies such rarity. A recent
publication and our own unpublished experience yields
(Table 3) 6 cases of grade 4 to 5 cardiovascular (thrombo-
sis/embolism) toxicity in a cohort of 128 patients. The
incidence of severe or life threatening cardiovascular tox-
icity in tables 2 and 3 was 0.1 versus 4.7%, p < 0.00001.
Jacobson et al found a 16.7% incidence of TE 48 patients
treated with definitive chemoradiation for cervical cancer.
Four of these 48 patients developed grade 4–5 TE. [9] Of
these 4 events, there were 3 grade 4 toxicities and 1 grade
5 toxicity. This is consistent with our unpublished institu-
tional experience with 1 grade 4 and 1 grade 5 toxicity in
a cohort of approximately 80 patients with pelvic malig-
nancies treated with radiation and cisplatin chemother-
apy, without erythropoietin.
The development of thromboembolic disease is depend-
ent upon the relationship between the factors of Vir-
chow's triad: stasis, hypercoagulability, and venous
injury. As first described by Trouseau in the nineteenth
century, and supported by modern publications, some
patients with malignancy are hypercoagulable and do
develop thromboses. [10,11] Simply from their malig-
nancy, in the absence of chemotherapy, one might expect
more than 2 reported cases of severe thrombotic events
out of the 1424 patients described in Table 2.
In addition to the increase of thromboses as a result of
malignancy, a review of chemotherapy associated vascular
toxicity suggests that chemotherapeutic agents may
increase the risk of thromboses by damaging vessel walls
or producing changes in the clotting cascade [12]. Feffer et
al. [13] reported that patients receiving chemotherapy for
breast cancer showed a statistically significant reduction
of functional protein C levels that returned to normal
upon completion of therapy. Icli and associates [14] sug-
gested that this severe vascular toxicity may be related to
hypomagnesaemia, autonomic dysfunction, alteration in
platelet aggregation, elevated plasma von Willebrand fac-
tor and hypercholesterolemia. Echoing these findings,
several recent publications suggest that the incidence of
venous thrombosis is further elevated in those patients
receiving chemotherapy. [15-17]
Through vascular injury and possible alterations in the
clotting cascade, chemotherapy agents such as cisplatin
have the ability to affect coagulability and cause vascular
injury, two aspects of Virchow's triad. Thus, though
unsupported by the data from the trials summarized in
Table 2, there is a theoretical basis to support the
increased incidence of TE reported in table 3.
Venous stasis is well documented to cause thromboem-
bolic events. The 6 events documented in Table 3 occurred
in cervix cancer patients. It might be hypothesized that
cervix cancer patients undergoing prolonged, in-patient
brachytherapy procedures may be at a high risk for the
development of DVT. Several retrospective studies of the
perioperative morbidity and mortality of gynecologic
brachytherapy have been performed [18-21]. These stud-
ies were performed in patients not receiving concurrent
cisplatin chemotherapy and no excess risk of TE was
described.
It remains possible that venous stasis during brachyther-
apy interacts with cisplatin to produce higher incidence of
thromboembolic events. However, only 1 of the 4 grade
Table 1: RTOG Cardiovascular (Thrombosis/Embolism) Toxicity Scoring
Grade
1 --------------
2 DVT not requiring anticoagulation
3 DVT requiring anticoagulation
4 Pulmonary embolism from thromboses
5 Death
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4–5 TE described by Jacobson was associated with brach-
ytherapy. Moreover, 6 of the 7 trials listed in Table 2 were
performed in cervix cancer patients who underwent
brachytherapy. Therefore, if the events in table 3 solely are
due to venous stasis during brachytherapy interacting
with cisplatin to produce higher incidence of thromboem-
bolic events, then the similar patients from the rand-
omized trials in Table 2 should have had a similar rather
than a statistically significant difference (p < 0.00001) in
incidence of TE.
Conclusion
Combining the results of a recent publication and our
own experience, we note 6 cases of grade 4 or 5 TE in
patients receiving cisplatin and concurrent irradiation
without erythropoietin for malignant disease including
two deaths from thromboses (Table 3). Such an incidence
is consistent with the known pro-thrombotic effects of
malignancy and chemotherapy. However, data from pro-
spective trials (Table 2) reported only 2 of 1424 having
grade 4 or 5 TE. The dramatic difference in incidence of
cardiovascular toxicity between Tables 2 and 3, raises the
possibility that cardiovascular toxicities (specifically
thrombosis, embolism) were inadequately reported on
the listed prospective trials.
For those patients enrolled in prospective trials, we sug-
gest that thromboses should be diligently documented
and reported. Only after the true incidence of thromboses
is established can we better evaluate the therapeutic ratio
of cisplatin therapy with or without novel agents such as
erythropoeitin. Also, this will allow the implementation
of appropriate levels of early screening and intervention
that may prevent life threatening complications.
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